期刊文献+

几种不同检测方法对结核性胸膜炎诊断价值分析 被引量:5

Analysis of the diagnostic value of three detection methods of tuberculous pleuritis
下载PDF
导出
摘要 目的探讨几种不同检测方法对结核性胸膜炎诊断价值。方法检测47例胸腔积液患者,其中37例经组织病理学或病原学明确诊断的结核性胸膜炎,10例诊断为恶性胸水。检测全部患者胸水中ADA活性、抗结核分枝杆菌抗体、结核分支杆菌特异性ELISPOT检测,经统计学处理后,评价各项指标对结核性胸膜炎诊断的灵敏度、特异度及临床诊断符合率。结果结核性胸水中腺苷脱氨酶(ADA)活性、结核分枝杆菌抗体,结核分支杆菌特异性ELISPOT检测,与恶性胸水组比较差别有统计学意义,P<0.05。以45U/L为临界值,胸水中ADA对结核性胸膜炎诊断的灵敏度为70.2%(26/37),特异度45%(9/20),临床诊断符合率为74.5%(35/47);胸水中结核分枝杆菌抗体检测对结核性胸膜炎诊断的灵敏度为62.2%(23/37),特异度为33.3%(7/21),临床诊断符合率为63.8%(30/47);以胸水中致敏T淋巴细胞含量40个为临界值,对结核性胸膜炎诊断的灵敏度为97.3%(36/37),特异度为90%(9/10)。临床诊断符合率为95.7%(45/47)。结论胸水中ADA活性、结核分枝杆菌抗体检测可提高结核性胸膜炎的诊断效能,而结核分支杆菌特异性ELISPOT检测可以达到更好的快速诊断效果。 Objectlve To investgate the diagnostic value of three detection methods of tuberculous pleuritis. Methods 47 patients of pleuritis were selected,among which 37 were tuberculous pletwitis diagnosed by histopathology or etiology,and 10 were malignancy. ADA level , TB-Ab and Mtb. specific antigens by ELISPOT way were measured, then investgated for sensitivity and specificity. Results There was significant difference between tuberculous and malignant pleural effusion, considering the level of ADA, TB-Ab and Mtb. specific antigens with ELISPOT. In patients with tuberculous pleuritis ,the sensitivity of ADA( 〉 45 U/L) ,TB-AB and Mtb. specific a,K, tigens( 〉40 sensitized T lymphocytes ) is 70.2%(26/37),62.2% (23/37),97.3% (36/37) respectively,and specificity is 45% (9/20) ,33.3% (7/21) ,90% (9/10) respectively,with diagnose accordance rate 74.5% (35/47) ,63.8% (30/47) ,95.7% (45/47) res..sespectively. Conclusion Detection of ADA level and TB-Ab in pleural effusion is useful to increase diagnosis efficacy, while Mib specific antigens by ELISPOT way is a fast diagnostic method.
出处 《中国实验诊断学》 北大核心 2009年第8期1042-1043,共2页 Chinese Journal of Laboratory Diagnosis
关键词 结核性胸膜炎 腺苷脱氨酶 结核分枝杆菌 特异性ELISPOT检测 tuberculosis pleuritis ADA TB ELISPOT
  • 相关文献

参考文献6

  • 1肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70-74. 被引量:2854
  • 2王森,张文宏.潜伏性结核感染的诊治进展[J].微生物与感染,2008,3(4):234-237. 被引量:18
  • 3Lalvani A. Diagaaosing tuberculosis infection in the 21 steentury: new tools to tackle an old enemy [ J ]. Chest, 2007,131 : 1898.
  • 4Mazurek GH, Jereb J , Lobue P, et at. Guidelines for usingthe Quanti FERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States[J] .MMWR Recomm Rep,2005,54:49.
  • 5National Institute for Clinical Excellence. Tuberculosis: national clinical guidelines for diagnosis, management , prevention, and controll London: Royal College of Physicians,2006 : Accessed at www. nice. org. uk.
  • 6Ariga H, Kawabe Y, Nagai H, et al. Diagnosis of Active Tuberculous Serosifis by Antigen-Specific Interferon-γ Response of Cavity Fluid Cells [J]. Cliuical Infectious Diseases,2007,45:1559.

二级参考文献20

  • 1刘剑君,幺鸿雁.我国结核病的流行现状和防治对策[J].预防医学论坛,2006,12(5):638-640. 被引量:54
  • 2World Health Organization. Gobal tuberculosis control: Surveillance, planning, financing. WHO Report 2005. Geneva, 2005,349
  • 3American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med , 2000, 161:221 -247
  • 4Centers for Disease Control and Prevention. Controlling tuberculosis in the United States :recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR,2005,54 : 1 - 81
  • 5Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med, 2004,350:2060 - 2067
  • 6Haley CA, Cain KP, Yu C, et al. Risk-based screening for latent tuberculosis infection. Southern Med J, 2008, 101 : 142 - 149
  • 7Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis. MMWR, 2000, 49:1-54
  • 8Ozekinci T, Ozbek E. Comparison of tuberculin skin test and a specific T-cell-based test, T-Spot. TB, for the diagnosis of latent tuberculosis infection. J Int Med Res, 2007, 35:696 - 703
  • 9Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest, 2007, 131:1898 - 1906
  • 10Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep, 2005, 54:49 - 55

共引文献2867

同被引文献48

  • 1Boom WH, Canaday DH, Fulton SA, et al. Human immunity to M. tuberculosis : T cell subsets and antigen processing. Tuberculosis ( Edinb), 2003,83 ( 1-3 ) :98-106.
  • 2Fritsch RD, Shen X, Sims GP, et al. Stepwise differentiation of CD4 memory T ceils defined by expression of CCR7 and CD27. J Immunol, 2005,175 (10) :6489-6497.
  • 3Beverley PC. Primer: making sense of T-cell memory. Nat Clin Pract Rheumatol, 2008,4 ( 1 ) :43-49.
  • 4Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol, 2008,8 (4) :247-258.
  • 5Mahairas GG, Sabo PJ, Hickey M J, et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol, 1996,178(5) :1274-1282.
  • 6Berthet FX, Rasmussen PB, Rosenkrands I, et al. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein ( CFP-10 ).Microbiology, 1998,144 ( Pt 11 ) :3195-3203.
  • 7Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen- specific T cells. Am J Respir Crit Care Med, 2001,163 (4) :824- 828.
  • 8Kim SH, Chu K, Choi SJ, et al. Diagnosis of central nervous system tuberculosis by T-cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Vaccine Immunol, 2008,15 (9) : 1356-1362.
  • 9Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet, 2003,361 (9364) :1168-1173.
  • 10Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J, 2006,28( 1 ) :31-34.

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部